Project Grant R43HL184750
Award Date 9/1/26
Completion Date 6/30/27
Dollars Obligated $309K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Palos Verdes Estates, CA 90274, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Actiox LLC $699,468 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) for development of a wearable microneedle-based biosensor for continuous cardiac troponin I monitoring. The assistance type is a Project Grant. Actiox will develop and optimize an electrochemical aptamer-based sensor integrated with microneedle arrays capable of real-time, ultra-sensitive monitoring of cardiac troponin I in interstitial...
- The National Heart, Lung, and Blood Institute awarded Prenosis, Inc. $1,218,102 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate the Heart Failure CardioScore, an artificial intelligence diagnostic tool for acute heart failure in emergency department patients. Prenosis will combine novel biomarkers and clinical data with machine learning to improve diagnostic and prognostic accuracy for acute heart failure, addressing the challenge...
- The National Heart, Lung, and Blood Institute awarded Resuscitation Innovations LLC $396,098 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and test an adjustable-pressure impedance threshold device for cardiac arrest resuscitation and post-resuscitation care. The recipient will refine the design of the Adjustable Pressure for Emergency Care (APEC) device, a dual-setting airway device with selectable cracking pressures of -6 and -12 centimeters of...
- The National Heart, Lung, and Blood Institute awarded Aventusoft LLC $500,000 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance commercialization of HEMOLINK, a skin-adhered disposable patch for non-invasive hemodynamic monitoring. HEMOLINK is a first-in-class wearable medical device featuring a synchronous quad-sensor array designed to estimate left ventricular end-diastolic pressure (LVEDP) for remote cardiac monitoring. The patch incorporates...
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute awarded Texas A&M Engineering Experiment Station $706,159 on August 19, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a smart wearable continuous cuffless blood pressure, cardiac, and respiratory monitoring system agnostic to skin tone. The recipient will design and build an innovative wearable device integrating multiple non-invasive physiological sensors on the wrist to provide health-grade continuous...
- The National Heart, Lung, and Blood Institute awarded Linshom Medical, Inc. $322,277 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct clinical evaluation of an alarm-activated detection system for early intervention of emerging respiratory decline using Linshom's FDA-cleared Continuous Predictive Respiratory Sensor (CPRS). The funding supports clinical development activities demonstrating the health economic value of the CPRS system, which...
- The National Heart, Lung, and Blood Institute awarded Sigt LLC $848,381 on September 1, 2026, to develop a clinical-grade intraoperative cardiac pulsed field ablation and lesion assessment system under the Cardiovascular Diseases Research program (CFDA 93.837), a Phase II Small Business Innovation Research project. Sigt LLC will develop a pulsed field ablation lesion assessment system (PFA-LAS) using proprietary high frequency dielectric sensing (HFDS) technology to enable intraoperative...
- The National Heart, Lung, and Blood Institute awarded Medluidics LLC $227,639 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a cardiopulmonary unit-on-a-chip for investigating right ventricular hypertrophy caused by pulmonary arterial hypertension and for developing targeted treatments. The recipient will develop a microfluidic device that models both the right ventricle and pulmonary artery separated by a collagen layer, enabling culture of...
- The National Heart, Lung, and Blood Institute awarded Tele-Stethoscope Inc. $406,367 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop Phase I algorithms and demonstrate technical feasibility for a mobile phone–based diagnostic tool that uses acoustic data to predict clinically significant spirometry and echocardiogram findings. The recipient will develop algorithms for predicting FEV1 percent predicted findings using mobile phone–captured...